Phase 4
Completed N=71
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Source: ClinicalTrials.gov NCT01815138 ↗Enrolled (actual)
71
Serious AEs
3.5%
Results posted
Sep 2017
Primary outcomePrimary: Ongoing Pregnancy — 15; 19 participants
◆ Published Evidence
Emerging
8citations · ~1 / year
Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization.
Summary
This a prospective randomized double blind study involving patients at high risk of OHSS development with peak serum E2 levels < 4,000 pg/ml comparing the ongoing pregnancy rates in patients who receive adjuvant hCG 1,000 IU at the time of GnRH agonist trigger or adjuvant hCG 1,500 IU 35 hours after GnRH agonist trigger.
Linked Publications
-
Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ongoing Pregnancy |
15; 19 | — |
| SECONDARY Ovarian Hyperstimulation Syndrome |
1; 3 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Normal baseline serum follicle stimulating hormone, polycystic ovarian syndrome (PCOS), Polycystic ovarian morphology, Previous high responder or previous OHSS, must have > 14 follicles of over 11 mm in diameter and with peak serum E2 levels = 4,000 pg/mL.
Data sourced from ClinicalTrials.gov (NCT01815138) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.